Lupus Nephritis Trials
The Division of Rheumatology strives to understand more about lupus through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
ORCHID-LN 20-1490 Susan Boackle, MD | The purpose of this study is to evaluate the safety and effectiveness of an investigational medicine in people with lupus nephritis. | • Between ages 18-75 • Diagnosed with class III or IV lupus nephritis • Had a kidney biopsy within the last 6 months | 303-724-0581, or email Karen Franklin or Hannah Meyer |
| |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.